Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto

This article was originally published in The Pink Sheet Daily

Executive Summary

Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.

You may also be interested in...



Daiichi’s Edoxaban A-Fib Claim May Be Limited By Renal Function

FDA clinical reviewers recommend approval of the Factor Xa inhibitor only for patients with renal impairment because of adverse efficacy results in patients with normal kidney function; at an Oct. 30 meeting, the cardio-renal advisory committee also will be asked to consider approval at a higher, untested dose.

Xarelto Indication Expansion Efforts Show That Fewer Could Be More

J&J and Bayer continue quest for acute coronary syndrome claim following three rejections by FDA; this time, Xarelto will be tested on top of only one antiplatelet drug instead of two.

Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play

A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel